Novel approaches are needed to assist rural primary care physicians in caring for older patients living with depression and pain who are at an elevated suicide risk. Read this article to find out more about the PREDICTOR model.
This study sought to identify patients vulnerable to worsening mental health during the early COVID-19 pandemic. Read this article to learn about the dramatic changes in psychiatric care experienced by these patients.
Both undertreatment and futile overtreatment can be disastrous. How can clinicians find the right balance? This ASCP Corner article discusses related ethical and practical issues and then delineates the "disease management approach."
Does rate of adherence to antidepressants vary much between physicians? This study of electronic health records and insurance claims data investigates the question, as well as whether adherence to medication is a good proxy for individual physician performance.
With more than 20 different pharmacologic options for the treatment of ADHD, how do you know what will work best for your patients? Read this systematic review to find out the most up-to-date information on treatment formulations for ADHD.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”